Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2010 07:53 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. CEO Granted New Patent by European Patent and Trademark Office Related to Potential Treatment for Memory Loss and Dementia

NEW YORK, Aug. 11, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
August 10, 2010 08:47 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Receives U.S. Patent Allowance for Alzheimer's Vaccine With Potential to Delay Onset or Prevent Alzheimer's Disease

NEW YORK, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
August 09, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Canadian Patent and Trademark Office

NEW YORK, Aug. 9, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent...
July 15, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Encouraged by Clinical Trial Data in Relation to Its Alzheimer's Immunotherapy Patents and Technology

NEW YORK, July 15, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
July 14, 2010 07:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Applauds Recent Media Coverage

NEW YORK, July 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
June 28, 2010 07:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. to Present at OneMedForum New York 2010 Emerging Company Finance Conference

NEW YORK, June 28, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
June 09, 2010 07:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Israeli Patent and Trademark Office

NEW YORK, June 9, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent...
June 03, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Receives Notice of Allowance for Alzheimer Monoclonal Antibody Patent from the United States Patent and Trademark Office

NEW YORK, June 3, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office...
May 06, 2010 07:54 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences and CARBOGEN AMCIS Reach Debt Settlement Agreement

NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease...
April 26, 2010 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Restructures Balance Sheet

NEW YORK, April 26, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's...